What is HC Wainwright’s Estimate for VTYX Q1 Earnings?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Ventyx Biosciences in a report released on Wednesday, November 5th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.07.

A number of other equities research analysts have also commented on the company. Oppenheimer raised their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ventyx Biosciences has a consensus rating of “Hold” and a consensus target price of $16.00.

Ventyx Biosciences Price Performance

NASDAQ VTYX opened at $9.00 on Thursday. The firm has a market cap of $641.79 million, a P/E ratio of -5.36 and a beta of 1.23. The stock’s 50-day moving average is $3.94 and its 200-day moving average is $2.81. Ventyx Biosciences has a one year low of $0.78 and a one year high of $9.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new position in Ventyx Biosciences in the first quarter worth approximately $28,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Ventyx Biosciences in the second quarter valued at approximately $71,000. Nuveen LLC bought a new position in shares of Ventyx Biosciences in the first quarter valued at approximately $194,000. Ieq Capital LLC bought a new position in shares of Ventyx Biosciences in the first quarter valued at approximately $223,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Ventyx Biosciences in the second quarter valued at approximately $38,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.